Edition:
United Kingdom

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

14.98USD
25 Apr 2018
Change (% chg)

$-0.02 (-0.13%)
Prev Close
$15.00
Open
$15.10
Day's High
$15.10
Day's Low
$14.89
Volume
3,095
Avg. Vol
4,887
52-wk High
$20.35
52-wk Low
$12.32

Latest Key Developments (Source: Significant Developments)

Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome
5:50am BST 

April 26 (Reuters) - Zealand Pharma A/S ::ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME.SAYS PIVOTAL PHASE 3 TRIAL IS ON TRACK FOR INITIATION IN Q3 2018.ZEALAND EXPECTS TO INITIATE PIVOTAL PHASE 3 TRIAL IN Q3 2018.SCIENTIFIC ADVICE WITH EUROPEAN MEDICINES AGENCY (EMA) IS ONGOING WITH AN EXPECTED OUTCOME BY MID-2018.  Full Article

Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu ::ZEALAND AND ROCHE DIABETES CARE ENTER PHASE 3 STUDY COLLABORATION FOR TREATMENT OF CONGENITAL HYPERINSULINISM WITH DASIGLUCAGON.SURGICAL TREATMENT FOR CHILDREN WITH CHI.PHASE 3 TRIALS OF DASIGLUCAGON ARE SET TO START IN SECOND HALF OF 2018.CHEK COMBO PUMP SYSTEM FOR STUDY.  Full Article

Zealand Pharma Enters Collaboration Agreement With Roche Diabetes Care
Wednesday, 11 Apr 2018 

April 11 (Reuters) - ZEALAND PHARMA A/S ::HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE.ZEALAND RESPONSIBLE FOR CONDUCTING PHASE 3 TRIALS, ROCHE DIABETES CARE PROVIDES ITS ACCU-CHEK COMBO PUMP SYSTEM.  Full Article

Zealand Pharma: Positive Results From First Phase 3 Trial For Treatment Of Severe Hypoglycemia
Tuesday, 20 Mar 2018 

March 20 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND PHARMA'S FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA SUCCESSFULLY MEETS ITS PRIMARY OBJECTIVE.‍RESULTS CONFIRM DASIGLUCAGON'S SAFETY PROFILE WITH NO TREATMENT-INDUCED OR TREATMENT-BOOSTED ANTI-DRUG ANTIBODIES​.‍ADDITIONAL RESULTS FROM THIS PHASE 3 TRIAL WILL BE AVAILABLE IN Q2 2018​.‍ADDITIONAL RESULTS FROM TRIAL ARE EXPECTED IN Q2 2018​.‍RESULTS FROM PIVOTAL PHASE 3 EFFICACY TRIAL ARE EXPECTED IN H2 2018.​.  Full Article

Zealand Pharma FY Net Loss At DKK 272.3 Million​
Wednesday, 7 Mar 2018 

March 7 (Reuters) - ZEALAND PHARMA A/S ::FY 2017 REVENUE DKK ‍​ 139.8 MILLION VERSUS DKK 234.8 MILLION YEAR AGO.‍FY NET LOSS FOR YEAR OF DKK 272.3 MILLION​.NO DIVIDEND HAS BEEN PROPOSED FOR 2017.FOR 2018, ZEALAND EXPECTS A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.‍​.NET OPERATING EXPENSES IN 2018 ARE EXPECTED TO BE WITHIN THE DKK 475-495 MILLION RANGE.‍​.  Full Article

Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES.  Full Article

Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017.ZEALAND REPORTS ROYALTY REVENUE OF DKK 11.3 MILLION/USD 1.8 MILLION FOR Q4 2017.‍IN Q4 SOLIQUA 100/33 SALES GREW 30% OVER PREVIOUS QUARTER​.ROYALTY REVENUE FOR 2017 AMOUNTED TO DKK 38.8 MILLION/USD 6.3 MILLION AN INCREASE OF 59% OVER PREVIOUS YEAR​.  Full Article

Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - ZEALAND PHARMA A/S ::ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC..POTENTIAL FUTURE INVESTMENTS OF UP TO USD 3.5 MILLION ARE LINKED TO CLINICAL DEVELOPMENT MILESTONES.COLLABORATES WITH BETA BIONICS TO ADVANCE DEVELOPMENT OF ITS DASIGLUCAGON IN ILET(TM).  Full Article

Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES.SAYS RESULTS FROM PHASE 3 TRIAL EXPECTED IN H2 2018​.  Full Article

Zealand Pharma Q3 operating loss at DKK 38.2 mln ​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - ZEALAND PHARMA A/S ::‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​.‍REVISED FINANCIAL GUIDANCE FOR 2017​.‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED​.‍NET OPERATING EXPENSES IN 2017 ARE EXPECTED TO BE WITHIN RANGE OF DKK 375-385 MILLION, 4-6 % LOWER THAN PREVIOUSLY GUIDED (DKK 390-410 MILLION).​.Q3 REVENUE DKK 40.1‍​ MILLION VERSUS DKK 39.6 MILLION YEAR AGO.2017 ‍OPERATING LOSS BEFORE ROYALTY INCOME/EXPENSES HAS BEEN REDUCED FROM DKK 290-310 MILLION TO DKK 275-285 MILLION​.‍FOR 2017, ZEALAND MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI​.Q3 OPERATING LOSS DKK 38.2 ‍​ MILLION VERSUS LOSS DKK 21.2 MILLION YEAR AGO.  Full Article

BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome

* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME